• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Lab Anal . Analytical performance evaluation of Lumipulse® SARS-CoV-2 antigen assay in 392 asymptomatic patients

tetano

Editor, Senior Moderator
J Clin Lab Anal


. 2023 Mar 27;e24867.
doi: 10.1002/jcla.24867. Online ahead of print.
Analytical performance evaluation of Lumipulse® SARS-CoV-2 antigen assay in 392 asymptomatic patients


Arnolfo Petruzziello[SUP] 1 [/SUP], Rocco Sabatino[SUP] 1 [/SUP], Livia Anna Catapane[SUP] 1 [/SUP], Carmela De Falco[SUP] 1 [/SUP], Antonella Petti[SUP] 1 [/SUP], Elena Tripaldelli[SUP] 1 [/SUP], Giovanna Loquercio[SUP] 1 [/SUP], Angela Annecchiarico[SUP] 2 [/SUP], Angela Salzillo[SUP] 3 [/SUP], Eugenio Caradonna[SUP] 4 [/SUP], Paolo Maggi[SUP] 5 [/SUP]



Affiliations

Abstract

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is one of the current public health care challenges. The main strategy adopted to prevent the spread of infection is the rapid identification of COVID-19-positive subjects. The aim of this study was to compare the performance of Lumipulse® antigen immunoassay with the real-time RT-PCR, the gold standard for the diagnosis of SARS-CoV-2 infection, in a strictly selected asymptomatic population.
Materials and methods: A total of 392 consecutive oro-nasopharyngeal swabs were collected from patients with no symptoms related to COVID-19 at the Emergency Department of AORN Sant'Anna e San Sebastiano, Caserta, Italy to evaluate the analytical performance of Lumipulse® SARS-CoV-2 antigen compared to qualitative real-time RT-PCR in asymptomatic patients.
Results: Lumipulse® SARS-CoV-2 antigen assay shows an overall agreement rate of 97% with a sensitivity of 96% and a specificity of 98%, with a PPV and NPV of 97%. The sensitivity varies according to the cycle threshold (C[SUB]t[/SUB] )-value reaching 100% and 86% with 15 < C[SUB]t[/SUB] < 25 and C[SUB]t[/SUB] ≥ 25, respectively. The ROC analysis yielded an AUC value of 0.98, suggesting that the antigen test may accurately detect SARS-CoV-2.
Conclusion: Our data showed that Lumipulse® SARS-CoV-2 antigen assay might be an efficient tool in the identification and limitation of SARS-CoV-2 transmission in large asymptomatic populations.

Keywords: COVID-19; RT-PCR; SARS-CoV-2 antigen; asymptomatic; comparison.
 
Back
Top Bottom